|
Mission Statement
Spencer Technologies is
dedicated to saving lives and significantly improving healthcare through the
advancement of non-invasive diagnosis, monitoring, and therapy. It is
an integrated patient service, clinical research, R & D, and manufacturing
company marketing innovative products and services through worldwide
customer relationships.
History
The
Company was founded to commercialize technology based on a series of pioneering
discoveries by Merrill P. Spencer, M.D., a co-founder and world leader in blood flow
diagnosis and monitoring. In 1987, Dr.
Spencer discovered that a non-invasive Doppler ultrasound device could detect particulate
blood emboli in real time. This is the only
known method available. Based on Dr.
Spencer’s work, Mark A. Moehring, Ph.D., Director of R & D at Spencer
Technologies, formulated a method of counting, sizing and characterizing these emboli as
solid or gaseous. This work is the basis for
the Company’s first patent awarded in the United States in 1994 and in Europe in
1997. Since then the Company has applied for 6 additional patents covering its technology.
Unique Philosophy
The Company operates a clinical diagnostic laboratory and surgical patient monitoring
service in the Seattle area under the name Spencer Vascular.
A
guiding principle of the Company is to promote synergy through day-to-day contact between
Company engineers and clinicians.
This allows the Company to incorporate the highest level of clinical utility
and relevance in its products.
Awards
For more information, please
contact:
Spencer Technologies
701 - 16th Avenue
Seattle, WA 98122
1-800-684-0586 (Toll free)
206-329-7220 (local)
206-329-7230 (fax)
info@spencertechnologies.com
|
